Positive Predictive Value of Cologuard Plus
The positive predictive value (PPV) of Cologuard for colorectal cancer is approximately 1-7%, while the PPV for advanced precancerous lesions plus colorectal cancer combined ranges from 24-28%, with the PPV for any colorectal neoplasia reaching 67%. 1, 2
PPV for Different Lesion Types
The PPV varies substantially depending on what you're looking for:
- Colorectal cancer alone: 0.25-1.3% 3, 1
- Advanced precancerous lesions (APL) plus cancer: 24-28% 1, 2
- Any colorectal neoplasia: 67% 1, 2
These figures come from real-world clinical practice data, not just the pivotal FDA trial. 1, 2
Context: Specificity and False Positive Rate
Cologuard has a specificity of 86.6%, meaning approximately 13-14% of tests will be false positives in patients without significant colorectal disease. 4 This translates to roughly 1 in 7 people without cancer or advanced lesions receiving a positive result. 4
For comparison, FIT demonstrates significantly better specificity at 94.9%, resulting in fewer false positives. 5, 4
PPV Across Multiple Screening Rounds
The PPV remains stable on repeat testing—the second round of Cologuard screening shows a PPV of 24% for advanced lesions, essentially identical to the 28% PPV on first-round testing (P = 0.12). 1 This consistency supports the utility of repeated Cologuard screening at 3-year intervals. 1
PPV in Patients with Prior Colonoscopy
Even in patients who previously had a normal colonoscopy, Cologuard maintains a PPV of 30% for advanced adenomas when the test is positive. 6 Among patients with prior colonoscopy exposure, the overall PPV for any colorectal neoplasia is 63%, compared to 73% in colonoscopy-naive patients. 2
Age-Related Variation
Specificity decreases with advancing age, dropping to 83% in persons over 65 years, which means older adults experience higher false positive rates approaching 17%. 4 This age-related decline is clinically important when counseling Medicare-eligible patients about expected outcomes. 4
Clinical Implications of the PPV
The modest PPV for cancer (1-7%) means that most positive Cologuard results will not represent colorectal cancer, but rather advanced adenomas or non-advanced neoplasia. 3, 1 However, this does not diminish the clinical utility, as detecting and removing advanced adenomas is a primary goal of colorectal cancer screening. 5
Any positive Cologuard result mandates follow-up colonoscopy within 6 months, regardless of the modest PPV for cancer specifically. 7 The high PPV for any neoplasia (67%) justifies this approach. 1, 2
Common Pitfall to Avoid
Do not dismiss a positive Cologuard result based on the low PPV for cancer alone—the combined PPV for cancer plus advanced adenomas (24-28%) and any neoplasia (67%) makes colonoscopy follow-up essential. 1, 2 The test is designed to detect precancerous lesions, not just invasive cancer. 5